New drug combo aims to boost immune attack on Hard-to-Treat cancers
NCT ID NCT02671435
First seen Jun 16, 2026 · Last updated Jun 20, 2026 · Updated 1 time
Summary
This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other targeted drugs. The trial is active but no longer recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Birmingham, Alabama, 35233, United States
-
Research Site
Scottsdale, Arizona, 85258, United States
-
Research Site
Duarte, California, 91010, United States
-
Research Site
La Jolla, California, 92093, United States
-
Research Site
Los Angeles, California, 90089, United States
-
Research Site
Sacramento, California, 95817, United States
-
Research Site
Santa Monica, California, 90404, United States
-
Research Site
Aurora, Colorado, 80045, United States
-
Research Site
Tampa, Florida, 33612, United States
-
Research Site
Chicago, Illinois, 60611, United States
-
Research Site
Baltimore, Maryland, 21231, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Detroit, Michigan, 48202, United States
-
Research Site
New Brunswick, New Jersey, 08903, United States
-
Research Site
New Hyde Park, New York, 11042, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
The Bronx, New York, 10461, United States
-
Research Site
Providence, Rhode Island, 02903, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Dallas, Texas, 75235, United States
-
Research Site
San Antonio, Texas, 78229, United States
-
Research Site
Salt Lake City, Utah, 84112, United States
-
Research Site
Blacktown, 2148, Australia
-
Research Site
Clayton, 3168, Australia
-
Research Site
Waratah, 2298, Australia
-
Research Site
Brussels, 1200, Belgium
-
Research Site
Edegem, 2650, Belgium
-
Research Site
Leuven, 3000, Belgium
-
Research Site
Vancouver, British Columbia, V5Z 4E6, Canada
-
Research Site
Toronto, Ontario, M5G 1Z5, Canada
-
Research Site
Marseille, 13385, France
-
Research Site
Nantes, 44093, France
-
Research Site
Debrecen, 4032, Hungary
-
Research Site
Milan, 20132, Italy
-
Research Site
Milan, 20141, Italy
-
Research Site
Grafton, 1023, New Zealand
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Seoul, 06591, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Madrid, 28027, Spain
-
Research Site
Madrid, 28034, Spain
-
Research Site
Málaga, 29010, Spain
-
Research Site
Pamplona, 31008, Spain
-
Research Site
Seville, 41013, Spain
-
Research Site
London, SW2 6JJ, United Kingdom
-
Research Site
Sutton, SM2 5PT, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab and monalizumab (immunotherapy drugs given by IV)
What this could lead to
If this combination works, it could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early-phase trial, so the drugs may not shrink tumors or improve survival. Side effects from immune system activation can be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.